IND submission for ONCR-021 still planned for mid-2023, subject to receipt of additional funding Ended the quarter with $45.0 million in cash, cash equivalents and investments ANDOVER, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today reported first quarter financial results and provided an update on its business. "Oncorus is pioneering a first-of-its-kind, self-amplifying RNA platform with an exciting lead program, ONCR-021, with plans to submit an IND with the FDA in mid-2023," said Theodore (Ted) Ashburn, M.D., Ph.D., Pres

-Former CEO of Dicerna brings deep expertise in RNA research, drug development, business development and financing- CAMBRIDGE, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced the appointment of Douglas M. Fambrough, III, Ph.D. to its board of directors. "We are thrilled to welcome Doug to our board and leverage his significant expertise and executive leadership skills as we work to advance our next-generation HSV and selectively self-amplifying vRNA/LNP platforms," said Theodore (Ted) Ashburn, M.D., Ph.D., President and Chief Executive Officer

CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), a viral immunotherapy company focused on driving innovation to transform outcomes for cancer patients, today announced the appointment of Richard Wanstall as Chief Financial Officer. "We are pleased to welcome Rick as our Chief Financial Officer and we look forward to drawing from his notable experience leading biotech companies through significant organizational growth," said Theodore (Ted) Ashburn, M.D., Ph.D., President and Chief Executive Officer of Oncorus. "Rick is a trusted colleague that I, as well as other members of the senior leadership team, have had the pleasure of working alongside in our previ

BERKELEY, CA / ACCESSWIRE / January 5, 2022 / Chameleon Biosciences Inc., a company developing the EVADERTM platform to produce next-generation gene therapies that are more potent and less immunogenic, announces today the appointment of Dr. Thomas Chalberg as Independent Board Director. Dr. Chalberg will provide crucial expertise in strategic growth as well as in gene therapy product development.Dr. Chalberg is a scientist, entrepreneur, and executive in Silicon Valley. He has spent the past 15 years developing novel therapies and life-changing products, particularly in the areas of oncology and ophthalmology. He has been recognized by the World Economic Forum as a Technology Pioneer, by All

CAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation viral immunotherapies to transform outcomes for cancer patients, today announced the appointment of Scott Canute, M.B.A. to its Board of Directors. Mr. Canute has nearly 40 years of broad experience in the biopharmaceutical industry, including leading global manufacturing and operations strategy and execution for Genzyme Corporation and Eli Lilly and Company. “As we execute on our growth plans, including the buildout of our in-house manufacturing capabilities, we are delighted to welcome Scott Canute to our Board of Directors,” said Theodo

Maxim Group initiated coverage of Oncorus with a rating of Buy and set a new price target of $35.00

SC 13G/A - Oncorus, Inc. (0001671818) (Subject)

SC 13G/A - Oncorus, Inc. (0001671818) (Subject)

SC 13G/A - Oncorus, Inc. (0001671818) (Subject)

SC 13D/A - Oncorus, Inc. (0001671818) (Subject)

SC 13D/A - Oncorus, Inc. (0001671818) (Subject)

SC 13D/A - Oncorus, Inc. (0001671818) (Subject)

SC 13D/A - Oncorus, Inc. (0001671818) (Subject)

SC 13G - Oncorus, Inc. (0001671818) (Subject)

SC 13G - Oncorus, Inc. (0001671818) (Subject)

SC 13G/A - Oncorus, Inc. (0001671818) (Subject)

DEFA14A - Oncorus, Inc. (0001671818) (Filer)

15-12G - Oncorus, Inc. (0001671818) (Filer)

DEFA14A - Oncorus, Inc. (0001671818) (Filer)

8-K - Oncorus, Inc. (0001671818) (Filer)

S-8 POS - Oncorus, Inc. (0001671818) (Filer)

S-8 POS - Oncorus, Inc. (0001671818) (Filer)

S-8 POS - Oncorus, Inc. (0001671818) (Filer)

S-8 POS - Oncorus, Inc. (0001671818) (Filer)

RW - Oncorus, Inc. (0001671818) (Filer)

8-K - Oncorus, Inc. (0001671818) (Filer)

Company now focused on the development of ONCR-021, Oncorus' lead self-amplifying RNA product candidate for non-small cell lung and other cancers; program remains on track for IND submission in mid-2023Phase 1 clinical trial of ONCR-177 in patients with advanced disease is being discontinuedPrioritization of ONCR-021 and reduction in workforce reduces company's cash burn rate; Oncorus reiterates guidance of cash runway into early 2024 ANDOVER, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), an RNA medicines company focused on developing IV administered, self-amplifying RNA to transform outcomes for cancer patients, today announced that it is reprioritizing its pipeli

Data presented from ongoing Phase 1 clinical trial of ONCR-177 in multiple solid tumor indications at RP2D at SITC 2021 and preclinical studies of ONCR-GBM targeting brain cancer at IOVC 2021Signed exclusive licensing agreement with Gaeta Therapeutics for use of locally delivered IL-12 via oncolytic viral expression in combination with immune checkpoint inhibitorsAdditional clinical data from ONCR-177 surface lesion monotherapy expansion and combination expansion cohorts expected in second half of 2022Continued to advance preclinical programs, including ONCR-021 towards IND filing in mid-2023Strengthened executive leadership team with promotion of John Goldberg, M.D., to Chief Medical Office

ONCR-177 was well tolerated with no dose-limiting toxicities in the surface lesion dose escalation part of the first-in-human study in heavily pretreated patients with advanced, injectable solid tumorsRecommended Phase 2 dose (RP2D) selected and expansion monotherapy cohort dosing is underwayThree of eight evaluable patients at RP2D across multiple indications (cutaneous melanoma, head and neck cancer, and mucosal melanoma) experienced clinical benefit after two doses of single-agent ONCR-177Proof of principle established for propriety Herpes Simplex Virus (HSV) platform that leverages microRNA attenuation to enable interferon resistance via retention of γ34.5 and five complementary immunomo

CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), a viral immunotherapy company focused on driving innovation to transform outcomes for cancer patients, today announced details of its upcoming presentation of initial data from the ongoing Phase 1 dose escalation and expansion clinical trial of ONCR-177 at the upcoming Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting, taking place November 12–14, 2021 in Washington, D.C. and virtually. ONCR-177, Oncorus' lead product candidate built on the company's oncolytic Herpes Simplex Virus (HSV) platform, is an intratumorally administered viral immunotherapy being developed for the treatment of multiple

To report initial data from ongoing Phase 1 clinical trial of lead oncolytic Herpes Simplex Virus (oHSV) viral immunotherapy candidate, ONCR-177, in multiple solid tumor indications at the upcoming Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting on November 12thCompleted Pre-IND meeting and initiating GLP IND-enabling safety and tolerability studies for lead intravenously (IV) administered Synthetic viral RNA (vRNA) immunotherapy candidate, ONCR-021 (Synthetic CVA21); plans to submit an IND for ONCR-021 in the first half of 2023Continues non-GLP safety and tolerability studies for second Synthetic vRNA immunotherapy candidate ONCR-788 (Synthetic SVV)First phase of GMP clinic

Continues to progress Phase 1 clinical trial of ONCR-177, company's lead oncolytic Herpes Simplex Virus (oHSV) viral immunotherapy candidate; on track to report initial interim data in 4Q'21Nominated company's first intravenously (IV) administered Synthetic viral RNA (vRNA) immunotherapy candidates, ONCR-021 (Synthetic CVA21) and ONCR-788 (Synthetic SVV)Anticipates first phase of GMP clinical manufacturing facility, including process development and quality control, to be completed in 2021, as previously guidedExpanded Board of Directors with appointments of Eric H. Rubin, M.D., and Barbara Yanni$159.9 million in cash and cash equivalents as of June 30, 2021 CAMBRIDGE, Mass., Aug. 04, 2021

Gainers Advanced Health (NASDAQ:AHI) stock increased by 127.0% to $1.68 during Wednesday's regular session. Trading volume for this security as of 13:37 EST is 84.4 million, which is 2216.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $47.0 million. LumiraDx (NASDAQ:LMDX) stock rose 25.0% to $0.44. Trading volume for this security as of 13:37 EST is 19.6 million, which is 8161.9% of its average full-day volume over the last 100 days. The company's market cap stands at $139.3 million. Ocean Biomedical (NASDAQ:OCEA) stock moved upwards by 22.74% to $6.53. Ocean Biomedical's stock is trading at a volume of 35.9 million shares as o

Gainers Advanced Health Intelligence Ltd. (NASDAQ:AHI) shares jumped 209.5% to $2.29 after the company signed a Letter of Intention with UAE-Based e-script medicine management company Pharmak Pharmacy. Ocean Biomedical, Inc. (NASDAQ:OCEA) shares gained 30.1% to $6.92 after the company announced a share price target increase to $17.63 by Fundamental Research Corp on results from an independent study showing glioblastoma tumor suppression, received patents and recent financing. LumiraDx Limited (NASDAQ:LMDX) shares surged 20% to $0.42 after the company received UK approval for its COVID Ultra and COVID & RSV Tests. Catalyst Biosciences, Inc. (NASDAQ:CBIO) gained 19.7% to $0.3489. PureC

Gainers Advanced Health (NASDAQ:AHI) stock increased by 143.2% to $1.8 during Wednesday's pre-market session. The market value of their outstanding shares is at $50.4 million. Ocean Biomedical (NASDAQ:OCEA) stock rose 38.34% to $7.36. The company's market cap stands at $250.3 million. LumiraDx (NASDAQ:LMDX) stock rose 27.42% to $0.45. The company's market cap stands at $142.0 million. Regulus Therapeutics (NASDAQ:RGLS) shares rose 18.97% to $1.63. The market value of their outstanding shares is at $31.7 million. Cardio Diagnostics Hldgs (NASDAQ:CDIO) shares moved upwards by 15.32% to $1.43. The company's market cap stands at $14.2 million. Fusion Pharmaceuticals (NASDAQ:FUSN) shares ro

Gainers Evelo Biosciences, Inc. (NASDAQ:EVLO) shares gained 91.5% to $0.2298 in pre-market trading. Evelo Biosciences shares jumped around 45% on Friday after the company won U.S. Patent for prebiotic compositions and methods of use thereof for modulation of the microbiome. EBET, Inc. (NASDAQ:EBET) shares surged 57% to $0.3010 in pre-market trading. EBET said Aspire shut down activities in Germany on May 7. Biofrontera Inc. (NASDAQ:BFRI) shares rose 47.7% to $0.65 in pre-market trading. Biofrontera recently started a contract manufacturer development of a portable photodynamic therapy lamp for use with Ameluz-PDT. Tivic Health Systems, Inc. (NASDAQ:TIVC) shares rose 29.2% to $0.1273 in

Gainers Biofrontera (NASDAQ:BFRI) shares rose 52.2% to $0.67 during Monday's after-market session. At the close, Biofrontera's trading volume reached 2.3 million shares. This is 3249.7% of its average volume over the last 100 days. The market value of their outstanding shares is at $17.8 million. Tivic Health Systems (NASDAQ:TIVC) stock rose 31.87% to $0.13. Today's trading volume for this security ended up closing at 5.9 million shares, which is 210.9 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $3.8 million. Cano Health (NYSE:CANO) stock increased by 25.6% to $1.57. Trading volume for this security closed at 2.1 million, accoun

Gainers Biofrontera (NASDAQ:BFRI) shares moved upwards by 52.3% to $0.67 during Friday's after-market session. Today's trading volume for this security ended up closing at 1.7 million shares, which is 2335.8 percent of its average volume over the last 100 days. The company's market cap stands at $17.8 million. Tivic Health Systems (NASDAQ:TIVC) shares increased by 26.7% to $0.12. Tivic Health Systems's trading volume hit 3.1 million shares by close, accounting for 112.0% of its average volume over the last 100 days. The market value of their outstanding shares is at $3.7 million. Evelo Biosciences (NASDAQ:EVLO) shares moved upwards by 23.26% to $0.16. Evelo Biosciences's trading volume hi

Gainers Oncorus (NASDAQ:ONCR) shares moved upwards by 144.6% to $0.19 during Friday's regular session. Trading volume for Oncorus's stock is 170.4 million as of 13:31 EST. This is 12952.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $4.9 million. Evelo Biosciences (NASDAQ:EVLO) stock increased by 119.66% to $0.18. As of 13:31 EST, Evelo Biosciences's stock is trading at a volume of 122.3 million, which is 2749.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $20.3 million. SCWorx (NASDAQ:WORX) stock moved upwards by 58.45% to $0.6. Trading volume for this security as o

Gainers Oncorus, Inc. (NASDAQ:ONCR) shares surged 258% to $0.2781. Evelo Biosciences, Inc. (NASDAQ:EVLO) shares jumped 216.2% to $0.2622 after the company won U.S. Patent for prebiotic compositions and methods of use thereof for modulation of the microbiome. Navidea Biopharmaceuticals, Inc. (NASDAQ:NAVB) gained 58% to $0.1296. Navidea Biopharmaceutical recently posted a narrower first-quarter loss. Virgin Galactic Holdings, Inc. (NYSE:SPCE) shares climbed 32.1% to $5.36 as the company announced the start of commercial spaceline operations. The company said its first commercial spaceflight, "Galactic 01," is set to fly between June 27 and June 30. Plutonian Acquisition Corp. (NASDAQ:PL

Oncorus, Inc. (NASDAQ:ONCR) shares are soaring Friday on abnormally high volume. The stock appears to be seeing increased attention ahead of the company's impending liquidation. What's Going On: Last Friday, the company's board announced it approved a liquidation and ONCR shares are set to be suspended from the Nasdaq on June 20.  On June 1, 2023, Oncorus announced its workforce reduction plan, which stated that the company is assessing all strategic options to maximize value for stakeholders, including an acquisition, merger, reverse merger, licensing, divesture of assets or other transactions Oncorus has an average session volume of just over 1.3 million, according to Benzinga Pro.